Merck
Trade Merck 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About MRK
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other.
MRK Key Statistics
MRK News
Pharma titans Merck (MRK), Pfizer (PFE) and Astellas Pharma (ALPMY) are delivering an "enormous new hope" for patients with an aggressive form of bladder cancer...
Merck (MRK) revealed that its Phase 3 KEYNOTE-B96 trial met a key secondary endpoint, as KEYTRUDA with chemotherapy improved overall survival in platinum-resist...
Merck & Co. Inc. (NYSE:MRK) announced data from the Phase 3 KEYNOTE-B96 trial (ENGOT-ov65) of Keytruda (pembrolizumab) in combination with chemotherapy (paclita...
Analyst ratings
55%
of 29 ratingsMore MRK News
Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near...
Merck (NYSE:MRK) announced on Thursday that its Phase 3 KEYNOTE-B96 trial for its anti-PD-1 therapy Keytruda reached the secondary goal related to the survival...
Merck (MRK) announced that the Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, met its secondary endpoint of overall survival, or OS, for the treatment of...
If you are staring at Merck’s stock chart and wondering whether now is the moment to jump in, hold steady, or walk away, you are not alone. Merck’s recent price...
The relentless pursuit of innovative treatments in the pharmaceutical industry continues to reshape the landscape of chronic disease management. Merck & Co. Inc...
Merck (MRK), known as MSD outside of the U.S. and Canada, announced the presentation of additional data from the Phase 3 studies of the investigational, once-da...
The pharmaceutical giant has seen brighter days. Turning $10,000 into $50,000 in about five years would require a compound annual growth rate (CAGR) of almost...
